Design and Rationale of the Phase 2 Baricitinib Study in Apolipoprotein L1-Mediated Kidney Disease (JUSTICE)

The JUSTICE trial is a Phase 2 study testing whether baricitinib, a JAK1/2 inhibitor, can reduce proteinuria in patients with APOL1-associated FSGS and hypertension-attributed chronic kidney disease by blocking APOL1 gene expression.